Pipeline
Development status (JP)
Development stage | Code name, generic name |
Indication | Origin | Development | Remarks |
---|---|---|---|---|---|
Filed | AK1820 (isavuconazonium sulfate) |
Aspergillosis, Mucormycosis and Cryptococcosis | Licensed:Basilea Pharmaceutica International Ltd, Allschwil | Asahi Kasei Pharma Corporation | Additional formulation |
Phase III | TA799, apraglutide | Short bowel syndrome | Licensed: VectivBio AG, an Ironwood Pharmaceuticals subsidiary | VectivBio AG, an Ironwood Pharmaceuticals subsidiary | Phase I in Japan was conducted by Asahi Kasei Pharma |
Phase II | ART-123, recombinant thrombomodulin alfa |
Chemotherapy- induced peripheral neuropathy (CIPN) | In-house | Asahi Kasei Pharma Corporation and Veloxis Pharmaceuticals | Additional indication Joint U.S.-Japan Phase I study in progress |
Phase II | AK1830 | Pain associated with osteoarthritis Chronic low back pain | Licensed:Array BioPharma Inc., a wholly owned subsidiary of Pfizer, Inc. | Asahi Kasei Pharma Corporation | |
Phase I | AK1910 | Autoimmune diseases | Licensed:SBI Biotech Co., Ltd. | Asahi Kasei Pharma Corporation |
Development status (Global)
Development stage | Code name, generic name |
Indication | Origin | Development | Region |
---|---|---|---|---|---|
Phase III | ART-123, recombinant thrombomodulin alfa |
Severe sepsis with coagulopathy | In-house | Asahi Kasei Pharma Corporation | United States, Europe, etc. |
Phase I | ART-123, recombinant thrombomodulin alfa |
Chemotherapy- induced peripheral neuropathy (CIPN) | In-house | Asahi Kasei Pharma Corporation and Veloxis Pharmaceuticals | United States |
Phase I | AK1320 | Spinal fusion surgery | In-house | Asahi Kasei Pharma Corporation | North America |
Development status (licensed out)
Development stage | Code name, generic name |
Indication | Origin | Development | Region |
---|---|---|---|---|---|
Phase II | LY3857210 | Chronic Pain | In-house (co-research with RaQualia Pharma Inc.) | Eli Lilly and Company | Global (AKP has rights to promote LY3857210 in Japan and China) |